Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Circadian RA Study in Rheumatoid Arthritis Subjects

Withdrawn

Conditions: Rheumatoid Arthritis

First Posted Date: 2017-06-07

Last Posted Date: 2019-06-14

Lead Sponsor: University of California, Davis

Registration Number: NCT03178955

Locations: 🇺🇸
UC Davis Center for Musculoskeletal Health, Sacramento, California, United States

Niclosamide With Etanercept in Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Placebo
Drug: Niclosamide
Drug: Etanercept

First Posted Date: 2017-05-19

Last Posted Date: 2018-12-12

Lead Sponsor: Faiq Gorial

Target Recruit Count: 110

Registration Number: NCT03160001

Locations: 🇮🇶
Baghdad teaching Hospital, Baghdad, Iraq

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Etanercept
Drug: Infliximab
Drug: Adalimumab
Drug: Golimumab
Drug: Certolizumab Pegol

First Posted Date: 2017-04-04

Last Posted Date: 2022-09-19

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 208

Registration Number: NCT03100253

Locations: 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹
Azienda Consorziale Ospedaliera Policlinico, Bari, Italy
🇮🇹
Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII, Bergamo, Italy

and more 19 locations

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Ixekizumab
Drug: Etanercept

First Posted Date: 2017-03-08

Last Posted Date: 2021-09-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 201

Registration Number: NCT03073200

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Modern Research Associates PLLC, Dallas, Texas, United States
🇲🇽
Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico

and more 66 locations